Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Income from Continuing Operations (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Income from Continuing Operations for 9 consecutive years, with 43358000.0 as the latest value for Q4 2025.

  • For Q4 2025, Income from Continuing Operations changed N/A year-over-year to 43358000.0; the TTM value through Dec 2025 reached 20890000.0, changed N/A, while the annual FY2025 figure was 20890000.0, 111.88% up from the prior year.
  • Income from Continuing Operations hit 43358000.0 in Q4 2025 for Soleno Therapeutics, up from 26013000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 43358000.0 in Q4 2025 and bottomed at 43773000.0 in Q1 2025.